Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

4.55

Margin Of Safety %

Put/Call OI Ratio

1.11

EPS Next Q Diff

1

EPS Last/This Y

3.91

EPS This/Next Y

5.23

Price

174.48

Target Price

230.01

Analyst Recom

1

Performance Q

4.19

Relative Volume

0.56

Beta

0.4

Ticker: ASND




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04ASND174.180.520.004331
2025-07-07ASND175.970.500.024434
2025-07-08ASND168.170.474.104652
2025-07-09ASND175.60.791.966160
2025-07-10ASND176.390.810.006284
2025-07-11ASND174.970.504.998513
2025-07-14ASND174.820.570.259129
2025-07-15ASND174.690.811.097023
2025-07-16ASND175.550.8129.167027
2025-07-17ASND177.231.1113.598196
2025-07-18ASND169.951.170.248406
2025-07-21ASND168.081.2111.866702
2025-07-22ASND165.541.360.897085
2025-07-23ASND170.071.360.047103
2025-07-24ASND168.511.353.187130
2025-07-25ASND167.491.340.107154
2025-07-28ASND164.371.340.057173
2025-07-29ASND163.251.400.027041
2025-07-30ASND167.721.390.447050
2025-07-31ASND173.491.340.067299
2025-08-01ASND174.181.111.137912
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04ASND174.1827.256.7-3.87
2025-07-07ASND175.9827.255.6-3.87
2025-07-08ASND168.1727.270.6-3.87
2025-07-09ASND175.7127.243.9-3.87
2025-07-10ASND176.4927.255.6-3.87
2025-07-11ASND174.9627.258.2-3.87
2025-07-14ASND174.8827.2117.9-3.87
2025-07-15ASND174.7527.2117.8-3.87
2025-07-16ASND175.5227.2116.4-3.87
2025-07-17ASND177.2027.2115.0-3.87
2025-07-18ASND170.1427.2126.7-3.87
2025-07-21ASND168.1127.2119.7-3.87
2025-07-22ASND165.5227.2120.7-3.87
2025-07-23ASND170.1427.2110.3-3.87
2025-07-24ASND168.3127.2119.4-3.87
2025-07-25ASND167.4731.5117.8-3.71
2025-07-28ASND164.6531.5120.5-3.71
2025-07-29ASND163.3231.5117.6-3.71
2025-07-30ASND166.7831.5111.5-3.71
2025-07-31ASND173.5031.4107.2-3.72
2025-08-01ASND174.4831.4115.6-3.72
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04ASND0.001.744.49
2025-07-07ASND0.001.754.49
2025-07-08ASND0.001.754.49
2025-07-09ASND0.001.754.49
2025-07-10ASND0.001.754.49
2025-07-11ASND0.001.753.77
2025-07-14ASND0.001.663.77
2025-07-15ASND0.001.663.77
2025-07-16ASND0.001.663.77
2025-07-17ASND0.001.663.77
2025-07-18ASND0.001.663.77
2025-07-21ASND0.001.603.77
2025-07-22ASND0.001.603.77
2025-07-23ASND0.001.603.77
2025-07-24ASND0.001.603.77
2025-07-25ASND0.001.604.55
2025-07-28ASND0.001.524.55
2025-07-29ASND0.001.524.55
2025-07-30ASND0.001.524.55
2025-07-31ASND0.001.524.55
2025-08-01ASND0.001.524.55
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.66

Avg. EPS Est. Current Quarter

-1.39

Avg. EPS Est. Next Quarter

-0.66

Insider Transactions

Institutional Transactions

1.52

Beta

0.4

Average Sales Estimate Current Quarter

136

Average Sales Estimate Next Quarter

182

Fair Value

Quality Score

28

Growth Score

54

Sentiment Score

84

Actual DrawDown %

5.2

Max Drawdown 5-Year %

-61.7

Target Price

230.01

P/E

Forward P/E

78.16

PEG

P/S

26.73

P/B

P/Free Cash Flow

EPS

-6.29

Average EPS Est. Cur. Y​

-3.72

EPS Next Y. (Est.)

1.51

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-93.22

Relative Volume

0.56

Return on Equity vs Sector %

156.3

Return on Equity vs Industry %

174.9

EPS 1 7Days Diff

-0.2

EPS 1 30Days Diff

0.15

EBIT Estimation

115.6
Ascendis Pharma A/S
Sector: Healthcare
Industry: Biotechnology
Employees: 1017
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today
news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance
stock history ASND – Ascendis Pharma A/S invest stock market
stock prices ASND premarket after hours
ticker ASND fair value insiders trading